Year: 2024

Erik Maris Joins Perella Weinberg

Written by Customer Service on November 18, 2024. Posted in Public Companies.

NEW YORK and PARIS, Nov. 18, 2024 (GLOBE NEWSWIRE) — Perella Weinberg Partners (Nasdaq: PWP), a leading global independent advisory firm, announced today that Erik Maris has joined the Firm’s European practice and will work with its French and European Partners in providing strategic advice to clients across coverage sectors. “Erik is an industry leader with extensive relationships, an impressive reputation, and a proven track record,” said Cyrille Perard, Partner and President of the Paris Bureau at Perella Weinberg. “His ability to provide innovative advice across a large span of industries is well recognized through corporate clients and financial sponsors. We are so happy to have him join the team and bolster the Perella Weinberg franchise in Europe.” Mr. Maris brings over 30 years of investment banking experience to Perella...

LexinFintech Holdings Ltd. to Report Third Quarter 2024 Unaudited Financial Results on November 25, 2024

Written by Customer Service on November 18, 2024. Posted in Public Companies.

SHENZHEN, China, Nov. 18, 2024 (GLOBE NEWSWIRE) — LexinFintech Holdings Ltd. (“Lexin” or the “Company”) (NASDAQ: LX), a leading credit technology-empowered consumer financial service enabler in China, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2024, after the U.S. market closes on Monday, November 25, 2024. The Company’s management will host an earnings conference call at 9:00 PM U.S. Eastern time on November 25, 2024 (10:00 AM Beijing/Hong Kong time on November 26, 2024). Participants who wish to join the conference call should register online at:https://register.vevent.com/register/BI220a892f574848f0b2997fb493e6296f Once registration is completed, each participant will receive the dial-in number and a unique access PIN for the conference call. Participants joining...

LEXIBOOK SALES S1 24-25: 24.6M€ VS 22.2M€ (+2.4M€, +11%). EBIT AND NET RESULT DOWN: +2.5M€ VS +3.5M€ IN S1 23-24, NET RESULT: +2.4M€ VS +3.1M€ IN 23-24.

Written by Customer Service on November 18, 2024. Posted in Earnings Releases And Operating Results.

LEXIBOOK SALES S1 24-25: €24.6M VS €22.2M (+€2.4M, +11%). OPERATING INCOME: +2.5M€ (-1.1M€ vs S1 23-24) DUE TO INCREASED ADVERTISING EXPENSES (+1.2M€) AND CHANGES IN METHOD OF ACCOUNTING FOR CERTAIN PROVISIONS. NET PROFIT WITHDRAWN TO +2.4M€ VS +3.1M€ IN 23-24.Over the half-year, sales in Europe (excluding France) were unchanged on the same period last year, while sales in France were up 16% on H1 23-24. Sales in the rest of the world rose sharply (+60%), driven in particular by growth in the United States, Revenues from licensed products rose by 15%. Non-licensed products also grew by 3%. Sales of licensed products account for 2/3 of total sales, a proportion consistent with sales for fiscal year 2023/2024, Advertising spend for the half-year was up 62% (€2.9M vs. €1.7 in H1 2023-24), Gross margin (margin 1) rose to €15.0M vs. €12.8M...

SalMar – Satisfactory financial results despite a period marked by biological challenges

Written by Customer Service on November 18, 2024. Posted in Earnings Releases And Operating Results.

Operational EBIT for Norway was NOK 1,082 million in the third quarter of 2024. The harvest volume was 56,400 tonnes, and operational EBIT per kg was NOK 19.2. Operational EBIT for the group was NOK 1,041 million in the third quarter of 2024. The harvest volume was 60,300 tonnes, and operational EBIT per kg was NOK 17.3. The farming segments in Norway were affected by biological challenges during the quarter, and volume expectations for 2024 have been reduced. Sales and industry reported historically strong results, where the efficient and flexible operational setup, along with the contract share, positively impacted the results. SalMar Aker Ocean completed the harvest of the remaining volume in 2024, and the production cycles for both Ocean Farm 1 and Arctic Offshore Farming are well underway, with planned harvesting in 2025. Icelandic...

REVISED – Sensus Healthcare Reports Third Quarter 2024 Financial Results With Revenues More than Doubling Versus 2023 Third Quarter

Written by Customer Service on November 18, 2024. Posted in Earnings Releases And Operating Results.

This revised news release replaces the one issued on November 14, 2024, contains several non-financial changes throughout and removes the name of and references to a new customer, at the customer’s request. The agreement with the new customer remains in effect.Revenues of $8.8 million compare with $3.9 million in the prior-year quarter, adjusted EBITDA (a non-GAAP measure) of $1.6 million compares with negative $1.7 million a year ago Expects to have more than 50 IG-SRT Systems signed under the Fair Deal Agreement recurring-revenue program by the end of the yearBOCA RATON, Fla, Nov. 17, 2024 (GLOBE NEWSWIRE) — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces...

Kaldvik AS (KLDVK): Q3 2024 Webcast results 20 November 2024 at 11:00 (CET)

Written by Customer Service on November 18, 2024. Posted in Public Companies.

A presentation of Kaldvik AS interim report Q3 2024 will be held at 11:00 (CET)/ 10:00 Icelandic time on the 20th of November 2024. The company’s CEO Roy-Tore Rikardsen and CFO Róbert Róbertsson will be presenting the company’s results. This session will be held in English via Teams. Questions may be asked after the session. Join the session by using this link: https://t.ly/4YB_C Kaldvik AS interim report Q3 2024 will be released on the 20th November 2024 at 7:00 (CET). Contacts: Róbert Róbertsson, CFO of Kaldvik AS: +354 843 0086(mobile) This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Apollo Opens Seoul Office and Names Jay Hyun Lee Head of Korea as Part of Continued APAC Expansion

Written by Customer Service on November 18, 2024. Posted in Public Companies.

Dr. Sam Young Chung to serve as Academic Advisor at Intersection of Retirement Solutions and Alternative Assets NEW YORK, Nov. 17, 2024 (GLOBE NEWSWIRE) — Apollo (NYSE: APO) today announced it has opened an office in Seoul and that Jay Hyun Lee has joined the firm as a Partner and Head of Korea to help execute and build on its growth plans in the market. Apollo has established a successful track record over more than 15 years in Asia Pacific, providing capital and retirement solutions to assist, support and partner with institutions across various geographies, including South Korea. The firm has grown its operational presence across Tokyo, Sydney, Hong Kong, Mumbai and Singapore since 2006. As Head of Korea, Lee will help drive Apollo’s capital formation strategy, institutional relationships and team growth in the country. He brings...

Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024

Written by Customer Service on November 17, 2024. Posted in Public Companies.

Data demonstrate potential superiority of a targeted protein degradation strategy compared to kinase inhibition for both BTK and IRAK4 targets in select inflammatory and autoimmune diseases SAN FRANCISCO, Nov. 17, 2024 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the presentation of preclinical data, including mechanism of action and relevant disease models, from two pipeline programs: NX-5948 and GS-6791. NX-5948 is Nurix’s proprietary, orally available, brain penetrant Bruton’s tyrosine kinase (BTK) degrader, which is being developed for the potential treatment of inflammation and autoimmune diseases in addition to its ongoing Phase 1b trial in...

Zhuding International Limited Signs Reverse Merger Agreement with Automated Water Solutions Inc. and Belisarian Holdings

Written by Customer Service on November 16, 2024. Posted in Mergers And Acquisitions.

HERTS, United Kingdom, Nov. 16, 2024 (GLOBE NEWSWIRE) — Zhuding International Limited (OTC: ZHUD), a Nevada corporation, and Automated Water Solutions Inc., (AWS), a Texas corporation, are pleased to announce the signing of a Reverse Merger Agreement for the acquisition of AWS by ZHUD that will result in AWS having control over ZHUD. The effective date of the merger is 10/31/24.An application for name change has been filed and the new name of the entity will be Automated Water Solutions Inc.. A stock symbol change will be forthcoming also. The new board of directors will be W. Kyle Lewis, John H. Slocum, Dennis M Sheib, Josh Cohen, and Jon M. Andrews. Automated Water Solutions Inc. “AWS” started as a vision over five years ago of where produced water recycling efficiency needed to be. Research and observation of the technologies...

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

Written by Customer Service on November 16, 2024. Posted in Public Companies.

Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time treatment of nex-z, supporting the hypothesis that greater TTR reduction may lead to a greater clinical benefit in ATTR amyloidosis Favorable trends consistently observed across multiple markers of cardiac disease progression at month 12 compared to baseline in an ATTR-CM population with a high proportion of advanced heart failure patients Consistent trend observed to date in ATTRv-PN arm, with stability or improvement of neuropathy as measured by multiple clinical measures of disease progression compared to baseline Persistently deep levels of serum TTR reductions following a single infusion remain virtually unchanged after two or more years of follow-up in over 25 patients Favorable safety and...

Year: 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals